Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is set to make a significant appearance at the BIO International Convention 2025 in Boston, where CEO Amir Reichman will outline the company's recent achievements. These include notable advancements in its Contract Development and Manufacturing Organization (CDMO) business and its innovative nanobody pipeline. The company's participation underscores its commitment to addressing unmet medical needs through cutting-edge biopharmaceutical solutions.
In a strategic financial move, Scinai has secured $1.38 million through a Standby Equity Purchase Agreement with Yorkville Advisors, a step that strengthens its capital base without the need for warrants or causing additional dilution for shareholders. This funding is pivotal as Scinai aims to meet its 2025 CDMO revenue guidance of $2 million and targets breakeven by 2026. The company's progress and financial strategies highlight its potential to make a lasting impact in the biopharmaceutical industry, offering promising developments for investors and stakeholders alike.
